BiotechTube

Bremelanotide

Phase 2Completed
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sexual Arousal Disorder

Conditions

Sexual Arousal Disorder

Trial Timeline

Feb 1, 2006 → May 1, 2007

NCT ID
NCT00425256

About Bremelanotide

Bremelanotide is a phase 2 stage product being developed by Pfizer for Sexual Arousal Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00425256. Target conditions include Sexual Arousal Disorder.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00425256Phase 2Completed

Competing Products

18 competing products in Sexual Arousal Disorder

See all competitors
ProductCompanyStageHype Score
DapoxetineJohnson & JohnsonPhase 3
77
Gardasil VaccineMerckPre-clinical
23
sildenafilPfizerApproved
84
sildenafilPfizerPhase 2
51
CP-866,087 + CP-866,087 + CP-866,087 + PlaceboPfizerPhase 2
51
PF-00446687 + PlaceboPfizerPhase 2
51
Sildenafil 100 mg + PlaceboPfizerPhase 2
51
AlfuzosinSanofiApproved
84
AVANAFIL + placeboSanofiPhase 3
76
Levitra (Vardenafil, BAY38-9456) + PlaceboBayerApproved
82
Placebo + 0.5 mgTestosterone + 10 mg BuspironeBrain BiotechPhase 2
44
Placebo + Testosterone + Buspirone hydrochlorideBrain BiotechPhase 2
44
Placebo + Sildenafil + TestosteroneBrain BiotechPhase 2
44
tibolone + estradiol-norethisteroneOrganonPhase 3
72
Bremelanotide + PlaceboPalatin TechnologiesPhase 3
69
bremelanotidePalatin TechnologiesPhase 2
44
BremelanotidePalatin TechnologiesPhase 3
69
EVO100 + PlaceboEvofem BiosciencesPhase 3
69

Other Products from Pfizer

MeropenemApproved
84
celecoxibApproved
84
13vPnCApproved
84
EtanerceptApproved
84
AtorvastatinApproved
84